Key words
vitamin D supplementation - metabolic profiles - pregnancy outcomes - pre-eclampsia
Abbreviations
CHD:
Coronary heart disease
DBP:
Diastolic blood pressure
FPG:
Fasting plasma glucose
FRAP:
Ferric reducing antioxidant power
GSH:
Glutathione
GDM:
Gestational diabetes
GPX:
Glutathione peroxidase
HOMA-IR:
Homeostasis model of assessment-estimated insulin resistance
HOMA-B:
Homeostasis model of assessment-estimated B cell function
hs-CRP:
High-sensitivity C-reactive protein
IOM:
Institute of Medicine
LBW:
Low birth weight
IL-:
Interleukin-6
MDA:
Malondialdehyde
MUFA:
Monounsaturated fatty acid
NO:
Nitric oxide
NAFLD:
Nonalcoholic fatty liver disease
OSI:
Oxidative stress index
PTH:
Parathyroid hormone
PUFA:
Polyunsaturated fatty acid
QUICKI:
Quantitative insulin sensitivity check index
ROS:
Reactive oxygen species
SFA:
Saturated fatty acid
SOD:
Superoxide dismutase
SBP:
Systolic blood pressure
TAC:
Total antioxidant capacity
TBARs:
Thiobarbituric acid reactive substance
T2DM:
Type 2 diabetes mellitus
TNF-α:
Tumor necrosis factor alpha
TDF:
Total dietary fiber
Introduction
Pre-eclampsia is a disorder characterized by pregnancy-induced hypertension and new-onset
proteinuria occurring after 20 weeks of gestation in a previously normotensive women
[1]. The prevalence of pre-eclampsia has reported between 1.3–6.7% of all pregnancies
[2]. Despite numerous attempts at early diagnosis and treatment, to date, no method
has been found that prevents the development of pre-eclampsia [3]. Increased biomarkers of oxidative stress are considered to be a key factor in pre-eclampsia
process [4]. In addition, decreased maternal plasma ascorbic acid concentrations [4], increased synthesis of free radicals and reactive oxygen species (ROS) in the placenta
[5], and reduced activities of antioxidant enzymes [6] may lead to the development of pre-eclampsia.
Various therapeutic strategies for prevention of pre-eclampsia are proposed including
the use of aspirin [7], antioxidant supplementation, especially vitamins C and E [8], and the use of low molecular weight heparin [9]. Previous studies have reported that intake of cholecalciferol supplements can rise
glutathione levels and reduce the production of lipid peroxidation products [10]
[11], which in turn, would result in decreased oxidative stress. These observations result
in the hypothesis that early supplementation with high-dose cholecalciferol could
be useful in decreased biomarkers of oxidative stress as well as improving vascular
endothelial function, thereby preventing or ameliorating the course of pre-eclampsia.
Taking 100 000 IU vitamin D supplements among patients with gestational diabetes (GDM)
showed improved insulin function, decreased total- and LDL-cholesterol concentrations
after 6 weeks [12]. In addition, in a meta-analysis study it has been shown that pregnant women who
received vitamin D supplements in early pregnancy had lower odds of pre-eclampsia
[13]. Vitamin D supplementation in healthy nulliparous women did affect pregnancy outcome
with regard to pre-eclampsia [14].
The favorable effects of cholecalciferol supplementation on metabolic profiles and
pregnancy outcomes might result from its effect on apolipoprotein gene expression
[15], parathyroid hormone (PTH) suppression [16], improved insulin sensitivity [17], and decreased production of lipid peroxidation products [11]. We are aware that no study had examined the beneficial effects of high-dose cholecalciferol
supplementation on metabolic profiles, biomarkers of inflammation, oxidative stress,
and pregnancy outcomes in pregnant women at risk for pre-eclampsia. The current study
was, therefore, performed to investigate the favorable effects of cholecalciferol
administration on metabolic status and pregnancy outcomes in pregnant women at risk
for pre-eclampsia.
Subjects and Methods
Participants
Between July 2014 and October 2014, we did a randomized double-blind placebo-controlled
clinical trial in Arak, Iran. For estimating sample size, we used a randomized clinical
study sample size formula where type 1 (α) and type 2 errors (β) were 0.05 and 0.20
(power=80%), respectively. According to a previous study [18], we also considered 0.9 as SD and 0.55 cm as the difference in the mean (d) of newborns’
length at birth as the key variable. Based on this, we needed 25 pregnant women in
each group to have 80% power of the study. However, we recruited 30 subjects in each
group (totally, 60 patients) to compensate for the probable loss to follow-up. In
the present study, our inclusion criteria were pregnant women primigravida, aged 18–40
years old and at risk for pre-eclampsia. Women were identified as “at-risk” by abnormal
uterine artery Doppler waveform (18–20 weeks’ gestation, mean resistance index>0.67
or pulsatility index>1.65 with or without the presence of unilateral or bilateral
diastolic notches) [19]. We excluded pregnant women who were unable or unwilling to give written informed
consent, having abnormal fetal anomaly scan, or were being treated with warfarin.
Gestational age was assessed from the date of last menstrual period and concurrent
clinical assessment [20]. The present trial protocol was approved by the Ethics Committee of Arak University
of Medical Sciences (AUMS) (Registration no. 92-12-161). All pregnant women signed
the written informed consent to take part in the current study. This study was registered
in the Iranian website (www.irct.ir) for registration of clinical trials (IRCT code: IRCT201410035623N27).
Study design
After stratification for pre-intervention BMI (< 25 and ≥25 kg/m2) and maternal age (< 30 and ≥30 years), pregnant women were randomly allocated into
2 groups to take either cholecalciferol supplements (n=30) or placebo (n=30). A trained
midwife at maternity clinic did the randomized allocation sequence with a computer
random number generator. An investigator with no clinical involvement in our study
packed cholecalciferol and placebos in numbered bottles based on the random list.
Randomization and allocation were hidden from the researchers and pregnant women until
the statistical analysis was completed. Pregnant women either received one oral pearl
containing of 50 000 IU vitamin D3 (D-Vitin 50 000; Zahravi Pharm Co, Tabriz, Iran)
or a placebo (Barij Essence Co, Kashan, Iran) every 14 days for 12 weeks from 20 to
32 weeks of gestation. Placebo pearls were similar in color, shape, size, and package
to the vitamin D3 ones and contained edible paraffin. Subjects were requested not
to alter their regular physical activity or normal dietary intakes throughout the
study and not to take any supplements other than the one provided to them by the investigators.
All pregnant women were also taking 400 μg/d folic acid from the start of pregnancy,
60 mg/d ferrous sulfate from the second trimester, and a multivitamin mineral capsule
(containing 400 IU vitamin D) from the second half of pregnancy. Both dietary and
physical activity records were taken at week 3, 6, and 9 of intervention. The dietary
records were based on estimated values in household measurements. To obtain nutrient
intakes of participants according to these 3-day food diaries, we used Nutritionist
IV software (First Databank, San Bruno, CA, USA) modified for Iranian foods.
Assessment of anthropometric variables
Information on pre-pregnancy weight and BMI were obtained from the records of pregnant
women existed in the clinic. A trained midwife at maternity clinic did anthropometric
measurements at the beginning of the study and the end of the intervention. Height
was measured without shoes using stadiometer with a precision of 0.1 cm. Weight was
measured in light clothing to the nearest 0.1 kg. BMI was determined as weight (kg)
divided by squared height (m2).
Primary and secondary outcomes
Primary outcomes were pre-eclampsia rate, low birth weight (LBW) (< 2 500 g), newborn’s
birth size, and preterm delivery (< 37 weeks). Secondary outcomes were metabolic concentrations,
biomarkers of inflammatory factors, oxidative stress, and blood pressures.
Biochemical analysis
Fasting blood samples (10 ml) were taken at baseline and 12 weeks after the intervention
at Arak reference laboratory at early morning after an overnight fast. Blood samples
were immediately centrifuged (Hettich 78532, Tuttlingen, Germany) at 3 500 rpm for
10 min to separate serum. Then, the samples were stored at −70°C before analysis at
the AUMS reference laboratory. Serum 25-hydroxyvitamin D concentrations was assayed
by a commercial ELISA kit (IDS, Boldon, UK). The inter- and intra-assay CVs for serum
25-hydroxyvitamin D assays ranged from 4.9 to 7.2%. Commercial kits were used to measure
fasting plasma glucose (FPG), triglycerides, cholesterol, VLDL-, LDL- and HDL-cholesterol
concentrations (Pars Azmun, Tehran, Iran). The intra- and inter-assay CVs for FPG
and lipid concentrations were <5%. Serum insulin was assayed by ELISA kit (Monobind,
CA, USA). The intra- and inter-assay CVs for serum insulin were 2.9 and 5.9%, respectively.
Homeostasis model of assessment-insulin resistance (HOMA-IR) and β-cell function (HOMA-B)
and quantitative insulin sensitivity check index (QUICKI) was calculated based on
suggested formulas [21]. Serum high sensitivity C-reactive protein (hs-CRP) was quantified using ELISA kit
(LDN, Nordhorn, Germany) with intra- and inter-assay CVs of 2.4 and 3.9%, respectively.
Plasma nitrite/nitrate (NOx), taken as an index of nitric oxide (NO) concentration,
was determined using the Giess method modified by Tatsh et al. [28]. Plasma total antioxidant capacity (TAC) was assessed by the use of ferric reducing
antioxidant power (FRAP) method developed by Benzie and Strain [22]. The plasma total glutathione (GSH) and malondialdehyde (MDA) were measured by the
method of Beutler et al. [23] and thiobarbituric acid reactive substance (TBARs) spectrophotometric test [24].
Statistical analysis
Distribution of data related to normality was assessed by Kolmogorov-Smirnov test.
Independent sample Student’s t-test was used to detect changes in general characteristics and dietary intakes between
the 2 groups. Comparisons of changes (endpoint minus baseline) 12 weeks after the
intervention between the 2 groups were done by two-way repeated measures analysis
of variance. In this analysis, the treatment (cholecalciferol vs. placebo) was regarded
as between-subject factor and time with 2 time-points (baseline and 12 weeks after
the intervention) was considered as within-subject factor. To control for confounding
variables, analysis of covariance (ANCOVA) test was used to determine the differences
between the 2 groups post-intervention, while adjusting for baseline measurements,
maternal age and baseline BMI. A p-value of <0.05 was considered as statistically
significant. All statistical analyses were done using the Statistical Package for
Social Science version 17 (SPSS Inc., Chicago, IL, USA).
Results
Totally, 60 pregnant [cholecalciferol (n=30) and placebo (n=30)] completed the trial.
On average, the rate of compliance in our study was high, such that 100% of pearls
were taken throughout the trial in both groups. Compliance with the consumption of
vitamin D supplements and placebos was monitored every 2 weeks through telephone interviews
and by the use of 3-day dietary records completed at week 3, 6, and 9 of intervention.
Mean age, pre-pregnancy weight and BMI of pregnant women was 27.4±5.2 years, 64.5±10.6 kg
and 25.9±4.6 kg/m2, respectively. Baseline and end-of-trial means of weight and BMI were not significantly
different between cholecalciferol and placebo groups (Data not shown).
Based on the three-day dietary records obtained throughout the intervention, no significant
change was seen between the two groups in terms of dietary intakes of energy, carbohydrates,
proteins, fats, saturated fatty acids (SFA), polyunsaturated fatty acids (PUFA), monounsaturated
fatty acids (MUFA), cholesterol, dietary fiber, vitamin D, calcium, phosphors, magnesium,
zinc, manganese, selenium, and vitamin C (Data not shown).
Pregnant women who received cholecalciferol supplements had significantly increased
serum 25-hydroxyvitamin D concentrations (+17.92±2.28 vs. +0.27±3.19 ng/ml, p<0.001)
compared with the placebo ([Table 1]). The administration of cholecalciferol supplements, compared with the placebo,
resulted in significant differences in serum insulin concentrations (+1.08±6.80 vs.
+9.57±10.32 μIU/ml, p<0.001), HOMA-IR (+0.19±1.47 vs. +2.10±2.67, p<0.001), HOMA-B
(+5.82±29.58 vs. +39.81±38.00, p<0.001) and QUICKI score (−0.009±0.03 vs. −0.04±0.03,
p=0.004). Furthermore, cholecalciferol-supplemented pregnant women had increased HDL-cholesterol
concentrations (+2.67±8.83 vs. −3.23±7.76 mg/dl, p=0.008) compared with the placebo.
Finally, cholecalciferol supplementation led to a significant rise in plasma TAC concentrations
(+79.00±136.69 vs. −66.91±176.02 mmol/l, p=0.001) compared with the placebo. There
were no significant differences between the cholecalciferol and placebo groups in
terms of changes in FPG, other lipid profiles, biomarkers of inflammation and oxidative
stress and blood pressures.
Table 1 Means (±standard deviation) of metabolic profiles, inflammatory factors, and biomarkers
of oxidative stress at baseline and after the intervention.
|
|
Placebo group (n=30)
|
|
|
Vitamin D group (n=30)
|
|
p **
|
|
Wk0
|
Wk12
|
Change
|
Wk0
|
Wk12
|
Change
|
|
|
Vitamin D (ng/ml)
|
17.10±2.21
|
17.37±4.04
|
0.27±3.19
|
16.99±1.40
|
34.91±2.36*
|
17.92±2.88
|
<0.001
|
|
FPG (mg/dl)
|
85.80±9.47
|
85.86±11.52
|
0.06±12.57
|
83.73±7.77
|
81.96±9.75
|
−1.77±13.07
|
0.58
|
|
Insulin (μIU/ml)
|
10.40±6.46
|
19.97±9.24*
|
9.57±10.32
|
10.95±8.31
|
12.03±4.87
|
1.08±6.80
|
<0.001
|
|
HOMA-IR
|
2.25±1.44
|
4.35±2.40*
|
2.10±2.67
|
2.29±1.82
|
2.48±1.14
|
0.19±1.47
|
<0.001
|
|
HOMA-B
|
39.65±26.27
|
79.46±34.83*
|
39.81±38.00
|
43.22±34.19
|
49.04±19.13
|
5.82±29.58
|
<0.001
|
|
QUICKI
|
0.35±0.04
|
0.31±0.02*
|
−0.04±0.03
|
0.34±0.03
|
0.34±0.02
|
−0.009±0.03
|
0.004
|
|
Triglycerides (mg/dl)
|
177.94±56.17
|
201.77±70.15*
|
23.83±50.11
|
176.49±70.85
|
205.68±62.80*
|
29.19±47.58
|
0.67
|
|
VLDL-cholesterol (mg/dl)
|
35.58±11.23
|
40.35±14.03*
|
4.77±10.02
|
35.29±14.17
|
41.13±12.56*
|
5.84±9.51
|
0.67
|
|
Total cholesterol (mg/dl)
|
221.78±38.68
|
230.03±34.95
|
8.25±30.44
|
202.09±41.07
|
222.47±44.29*
|
20.38±28.02
|
0.11
|
|
LDL-cholesterol (mg/dl)
|
116.87±31.37
|
123.59±29.65
|
6.72±23.04
|
101.17±30.65
|
112.86±39.06
|
11.69±41.19
|
0.56
|
|
HDL-cholesterol (mg/dl)
|
69.31±9.87
|
66.08±11.22
|
−3.23±7.76
|
65.61±8.70
|
68.28±7.78
|
2.67±8.83
|
0.008
|
|
Total: HDL cholesterol ratio
|
3.27±0.70
|
3.56±0.82*
|
0.29±0.50
|
3.08±0.49
|
3.26±0.51
|
0.18±0.60
|
0.99
|
|
hs-CRP (ng/ml)
|
8 061.56±3 443.16
|
7 582.36±3 303.68
|
−479.20±3 105.71
|
6 927.46±4 753.22
|
5 882.75±4 787.08
|
−1 044.71±3 488.00
|
0.51
|
|
NO (μmol/l)
|
54.53±10.42
|
59.65±10.82
|
5.12±13.95
|
50.43±5.88
|
49.99±6.51
|
−0.44±7.22
|
0.05
|
|
TAC (mmol/l)
|
690.11±141.95
|
623.20±126.07*
|
−66.91±176.02
|
678.18±125.57
|
757.18±136.43*
|
79.00±136.69
|
0.001
|
|
GSH (μmol/l)
|
581.29±165.96
|
475.45±165.44*
|
−105.84±142.62
|
569.56±233.01
|
479.03±140.33
|
−90.53±242.13
|
0.83
|
|
MDA (μmol/l)
|
4.99±0.85
|
5.39±0.89
|
0.40±1.27
|
5.23±0.85
|
5.48±0.79
|
0.25±0.78
|
0.59
|
|
SBP (mm Hg)
|
108.33±6.52
|
111.33±6.14
|
3.00±8.27
|
104.66±7.53
|
108.00±5.95*
|
3.34±7.11
|
0.67
|
|
DBP (mm Hg)
|
73.50±4.76
|
78.00±5.95*
|
4.50±5.92
|
74.00±6.21
|
75.83±4.92
|
1.83±7.71
|
0.13
|
*Obtained from repeated measures ANOVA test. ** Different from baseline study, p<0.05
For abbreviations, see text
Baseline levels of SBP were significantly different between the 2 groups. Therefore,
we controlled the analyses for the baseline levels. However, after this adjustment
no significant changes in our findings occurred, except for plasma NO levels (p<0.001)
Table S1. Further adjustments for maternal age and baseline BMI did not affect our
findings, except for serum HDL-cholesterol levels (p=0.06) and systolic blood pressure
(SBP) (p=0.04).
We did find no significant change in cesarean section rate, gestational age, preterm
delivery, newborn’s birth size, Apgar scores, pre-eclampsia rate and LBW comparing
the 2 groups ([Table 2]).
Table 2 The effect of vitamin D supplementation on pregnancy outcomes.*
|
Placebo group (n=30)
|
Vitamin D group (n=30)
|
p **
|
|
Cesarean section (%)
|
10 (33.3)
|
9 (30.0)
|
0.78†
|
|
Gestational age (weeks)
|
39.1±1.3
|
39.4±1.3
|
0.31
|
|
Preterm delivery (%)
|
1 (3.3)
|
0 (0)
|
0.31†
|
|
Newborns’ weight (g)
|
3 141.0±495.9
|
3 313.6±341.1
|
0.12
|
|
Newborns’ length (cm)
|
50.4±2.1
|
50.9±1.5
|
0.29
|
|
Newborns’ head circumference (cm)
|
34.7±1.5
|
34.4±0.8
|
0.26
|
|
1-min Apgar score
|
8.9±0.2
|
8.9±0.3
|
0.30
|
|
5-min Apgar score
|
9.9±0.2
|
9.9±0.3
|
0.30
|
|
Pre-eclampsia rate (%)
|
3 (10.0)
|
1 (3.3)
|
0.30†
|
|
LBW (%)
|
2 (6.7)
|
0 (0)
|
0.15†
|
*Values are means±SDs
** Obtained from independent t-test
† Obtained from Pearson Chi-square test
For abbreviation, see text
Discussion
The current study demonstrated that high-dose vitamin D administration among women
at risk for pre-eclampsia had beneficial effects on insulin metabolism parameters,
serum HDL-cholesterol, and plasma TAC concentrations, but did not affect FPG, other
lipid profiles, inflammatory factors and other biomarkers of oxidative stress. To
the best of our knowledge, the current study is the first evaluating the effects of
high-dose cholecalciferol administration on metabolic status and pregnancy outcomes
in pregnant women at risk for pre-eclampsia according to abnormal uterine artery Doppler
waveform. It must be kept in mind that participants in the current study were pregnant
women who have vitamin D deficiency by definition and in addition they have a very
low vitamin D intake. Therefore, vitamin D supplementation with appropriate dosage
is suggested in vitamin D deficient pregnant women. In addition, we used a dose of
approximately 4 000 IU vitamin D supplements daily in the current study, which is
higher than the current recommended dietary allowance (600 IU/day) or standard prenatal
supplement dose (400 IU/day). However, this dose is the tolerable upper intake levels
advised by the Institute of Medicine (IOM) [25] and this is no problem in this short study of 12 weeks.
Pre-eclampsia is associated with fetal and maternal complications [26]. Our study demonstrated that high-dose cholecalciferol intake for 12 weeks in women
at risk for pre-eclampsia resulted in significant differences in serum insulin concentrations,
HOMA-IR score, HOMA-B, and QUICKI score compared with the placebo, but did not affect
FPG. Moreover, only limited data are available assessing the beneficial effects of
cholecalciferol administration on metabolic status in pregnant women at risk for pre-eclampsia.
Among women without risk for pre-eclampsia as well as in animal models, the favorable
effects of taking vitamin D on glucose homeostasis parameters have been shown. In
agreement with our study, Soheilykhah et al. [27] showed that 50 000 IU cholecalciferol intake every 2 weeks from week 12 of pregnancy
until delivery led to improved insulin resistance in healthy pregnant women. In our
previous study among women with GDM, we also observed improved markers of insulin
metabolism following the consumption of 100 000 IU cholecalciferol supplements for
6 weeks [12]. However, some researchers did not see such beneficial effects of cholecalciferol
administration on insulin function. For instance, taking vitamin D supplements had
no beneficial effects on insulin resistance in patients with type 2 diabetes mellitus
(T2DM) after 24 weeks of intervention [28] and after 6 months of therapy [29]. Furthermore, supplementation with 1 000 IU vitamin D daily did not affect insulin
resistance among healthy overweight or obese women for 12 weeks [30]. Impaired insulin metabolism is associated with arterial stiffness and coronary
heart disease (CHD) independent of glucose tolerance status and increased hypertension
[31]. Increased cholecalciferol concentration suppression of inflammatory factors and
increased expression of the insulin receptor and/or proteins of the insulin-signaling
cascade may result in improved insulin function [32].
Findings from the current study showed that pregnant women who received high-dose
of vitamin D supplements had a significant rise in serum HDL-cholesterol concentrations
compared with the placebo, but had no significant improvement in other lipid profiles.
In line with our study, a 2-month supplementation of 100 000 IU vitamin D increased
HDL-cholesterol concentrations in school children [33]. In addition, vitamin D plus calcium administration (400 IU of vitamin D3 daily+1 000 mg
of elemental calcium) resulted in a significant increase in HDL-cholesterol concentrations
among postmenopausal women [34]. However, some researchers did not observe any significant effect of taking cholecalciferol
supplements on lipid concentrations [35]
[36]. Increased HDL-cholesterol concentrations in the presents study may result from
form the stimulation of apolipoprotein A1 by cholecalciferol [37]. The absence of significant effect of taking cholecalciferol supplements on other
lipid profiles in our study might be explained by distinct trial designs, various
dosages of cholecalciferol supplementation, and subjects of the study.
We have revealed here that the administration of cholecalciferol supplements did not
affect serum hs-CRP and plasma NO levels in pregnant women at risk for pre-eclampsia.
In accordance with the present study, no significant change in CRP concentrations
was observed after the vitamin D intake (1 000, 2 000, or 4 000 IU/day of vitamin
D3 orally) for 3 months [38]. Furthermore, 1 000 mg calcium per day and 50 000 IU vitamin D3 pearl 2 times during
the study (at study baseline and day 21 of intervention) co-supplementation did not
affect hs-CRP and NO concentrations among GDM patients after 6 weeks [10]. In disagreement, a 9-week administration of 400 IU vitamin D supplements was associated
with a significant decrease in serum hs-CRP concentrations among healthy pregnant
women [39]. In addition, in an in vitro study, concomitant incubation with 1,25(OH)₂D reduced
interleukin-6 (IL-6) by 32%, and of IL-8 levels by 34% [40].
We have demonstrated that high-dose cholecalciferol intake resulted in a significant
rise in plasma TAC concentrations in pregnant women at risk for pre-eclampsia compared
with the placebo, but did not influence on other biomarkers of oxidative stress. In
consistent with this trial, cholecalciferol supplementation significantly decreased
liver oxidative stress index (OSI) and improved serum TAC concentrations in diabetic
rats [41]. In addition, our findings are in accordance with those reported by other researchers,
showing decreased oxidative DNA damage in the normal human colorectal mucosa following
cholecalciferol and calcium supplementation [42]. However, supplementation of 50 000 IU vitamin D3 every 14 days for 4 months among
adult patients with nonalcoholic fatty liver disease (NAFLD) did not affect TAC concentrations,
but led to amelioration in MDA concentrations [11]. Increased oxidative stress and free radicals is regarded as a main factor in the
pathogenesis and progression of diabetes mellitus and cardiovascular complications
[43]. Accurate explanation to the antioxidative effects of cholecalciferol supplements
cannot be provided, but these may include stabilization of the plasma membrane against
lipid peroxidation [44] or upregulation of antioxidant systems including glutathione peroxidase (GPX) and
superoxide dismutase (SOD), via its nuclear receptors [45].
The current study revealed no significant effect of high-dose cholecalciferol supplementation
on pregnancy outcome. Our findings are accordance with previous studies showing supplementation
with cholecalciferol did show no association between maternal vitamin D status in
HIV-infected pregnant women and adverse pregnancy outcomes [46]. In addition, taking 25 mg/d ergocalciferol in pregnant women did not influence
mean birth weight in other studies [47]
[48]. Others did not find a significant effect of vitamin D effect on pregnancy outcomes
[49]
[50]. Discrepancies between our study and others might be explained by the different
doses of cholecalciferol used as well as participants of the study.
While interpreting some limitations need to be taken into account. Due to limited
funding, we in the current study did not assess the effect of cholecalciferol administration
on other biomarkers of systemic inflammation including interleukin 1(IL-1), IL-6,
and tumor necrosis factor alpha (TNF-α) as well as biomarkers of oxidative stress
such as catalase and SOD. Furthermore, the appropriate dosage of vitamin D supplementation
in pregnant women with at risk for pre-eclampsia cannot be inferred from this study
and additional data would be required.
In conclusion, the administration of cholecalciferol supplementation for 12 weeks
had favorable effects on insulin metabolism parameters, serum HDL-cholesterol and
plasma TAC concentrations, while it did not affect FPG, other lipid concentrations,
inflammation, oxidative stress, blood pressures, and pregnancy outcomes.
Author Contributions
ZA contributed in conception, design, statistical analysis, and drafting of the manuscript.
MK and EB contributed in conception, data collection, and manuscript drafting. All
authors read and approved the final version of the paper. ZA is the guarantor of this
work.
Note of Concern
Since publication of this article, serious concerns have been
raised about the integrity of the reported methods, results
and analysis. Responses by the leading author and ethics
committees have been unsatisfactory and inconclusive; we
advise readers to interpret the information presented in the
article with due caution.
